Kuvura kanseri ikomeye ya kanseri

Kanseri nini y'ibihaha (LCLC) ni ugukaza kanseri ntoya y'ibihaha (NSCLC). Kuvura akenshi bikubiyemo guhuza ibitsina, kuvura imiyoboro, imivura igamije, hamwe na imyuka, ubuzima bwihariye bwumurwayi, ubuzima bwihariye, nibiranga ibibyimba byihariye. Iterambere rya vuba muburyo bwa molecular nigisubizo cyihariye ni ugutezimbere ibisubizo kubasuzumwe hamwe na LCLC.UKURI KUGARAGAZA KUNYARWANDA NINI BIBIRIMBWA BISANZWE?Kuvura kanseri nini ya selile (LCLC) ni ubwoko bwa kanseri ntoya ya selile. Ibona izina ryayo kuva kumurongo munini, udasanzwe ureba munsi ya microscope. LCLC ikunda gukura no gukwirakwira vuba, gukora isuzuma hakiri kare no kuvura bufatanye. Mugihe bisanzwe ugereranije nubundi bwoko bwa NSCLC, gusobanukirwa ibiranga ni ngombwa mu micungire myiza.Ibintu byangiza izindi mparo, kunywa itabi ni ibintu bifatika bya LCLC. Ibindi bintu bishobora guteza ibyago birimo guhura numwotsi witabi, muri RADON, asisetosi, nibitekerezo byinganda. Kureka itabi, wirinde guhura na carcinorogene izwi, kandi kubungabunga ubuzima bwiza ni ingamba nziza zo gukumira. Kugenzura Kanseri isanzwe hamwe na kanseri y'ibihaha kubantu bafite ibyago byinshi barashobora kandi gufasha mugutahura hakiri kare kandi birashoboka ko bitezimbere Kuvura kanseri nini ya selile Ibisubizo.Troatement Amahitamo yibihaha binini bya selile akenshi niwo murongo wambere wo kuvura LCLC yo hakiri kare LCLC, mugihe ikibyimba cyaho kandi kidakwirakwira kurubuga rwa kure. Uburyo bwo kubaga bushobora kuba bukubiyemo gukuraho igice cyibihaha (wedge wenyine cyangwa segmenstectomy), lobe yose (lobectomy), cyangwa nibihaha byose (pnemonectombe). Guhitamo kubaga biterwa nubunini n'ahantu h'ibibyimba, kimwe nimikorere yo mu bihaha muri rusange. Shandong Baofa Kanseri Amakipe yubushakashatsi yiboneye cyane muri ubu buryo. Memotimotherapychemotherapie ni uburyo bwa sisitemu ikoresha ibiyobyabwenge kugirango yice kanseri kumubiri. Bikoreshwa cyane muguhuza no kubaga cyangwa kuvura imirasire, cyangwa nkubwiteganyi bwambere bwambere. Ubutegetsi busanzwe bwa chimiotherapy kuri LCLC irimo ibiyobyabwenge bishingiye kuri platinum (nka Cisplatin cyangwa Carboplatin) hamwe nabandi bakozi ba chemitherapie. Ingaruka ziterwa na chimiotherapie zirashobora kubamo isesemi, umunaniro, igihombo cyumusatsi, no kongera ibyago byo kwandura. Umuvugizi wo kuvura Irashobora gukoreshwa muguvura LCLC muburyo butandukanye: Mugihe kwibanze kuba abarwayi batari kuba ababandida kubaga, cyangwa kugabanya ibimenyetso nkububabare cyangwa kubura umwuka mu gihe cyateye imbere. Ubwoko bwimikorere ya Radiap ikoreshwa kuri LCLC irimo imivugo ya Braam (EBrt) hamwe na Stereotactike Kuvura imivugo yumubiri (SBRT) .Ibikoresho bya Stereontact. Izi mvugo zingirakamaro cyane kubantu bafite imiterere yihariye mubibyimba byabo. Intego zisanzwe muri LCLC zirimo egfr, alk, ros1, na braf. Mbere yo gutangira kuvura, mubisanzwe abarwayi barimo kugerageza molekoclar kugirango bamenye niba ibibyimba byabo bifite kimwe muribi byateganijwe. Niba ukeneye ubufasha, kanseri yubushakashatsi bwa kanseri irashobora gutanga serivisi zipiganwa.imMunotherapimMunotherapy Harses ifite imbaraga z'umubiri wo kurwanya kanseri. Abagizi ba nabi bagenzura, nka Pembezimab, NIVOLUMAB, na Lizalizimab, ni ubwoko bwumupfumu buhagarika poroteyine irinda gahunda zubumuga zitera kanseri. Imhumupfurapi yerekanaga ingaruka zitanga ibisubizo muri LCLC, cyane cyane kubarwayi bafite ibibyimba byerekana urwego rwo hejuru rwa PD-L1. Irashobora gukoreshwa nkumurongo wambere-kuvura inyuguti zambere cyangwa nyuma ya chimiotherapi yananiwe.Ibikoresho binini bya kanseri ya selile kugirango ugaragaze ibibyimba byihariye kugirango umenye iterambere ryihariye. Aya makuru arashobora gufasha abaganga guhitamo uburyo bukwiye bwo kuvura cyangwa impfumuro kuri buri murwayi. Gukurikirana-Igisekuru gikurikira (Ngs) ni tekinike isanzwe ikoreshwa mugutandukanya molecular, yemerera icyarimwe, yemerera icyarimwe no gutahura ibintu byinshi bya genetic.Umugore Kuvura kanseri nini ya selile kumurwayi kugiti cye ukurikije umwirondoro wa moleki, ubuzima rusange, hamwe nibyo ukunda. Ubu buryo bugamije kugwiza imikorere yo kwivuza mugihe tugabanije ingaruka mbi. Imiti yihariye iragenda ihinduka ingenzi mu micungire ya LCLC, nkuko bituma abaganga bahitamo ingamba zikwiye zo kuvura kuri buri shami ry'ibigeragezo. Kwitabira ikigeragezo cy'amavuriro birashobora guha abarwayi kubona gukata-inkombe zitaraboneka cyane. Ibigeragezo by'amakuba ni igice cyingenzi cyo gutera inkunga kanseri, kandi abarwayi bagomba kuganira nabaganga babo niba bahuye nibikorwa byiza kuri bo. Icyambere-Icyiciro LCLC ifatwa no kubaga ifite prognose nziza kuruta amajyambere ya LCLC yakwirakwiriye kurubuga rwa kure. Gutera imbere mu kuvura, nk'ibitekerezo bigamije no kudahindura impinduko, byateje imbere ibipimo byo kubaho ku barwayi hamwe na LCLC mu myaka yashize. Umubare w'imyaka 5 yo kubaho kuri kanseri idafite ntoya (NSCLC) ku cyiciro1 Icyiciro cya Stande imyaka 5 30%. Icyitonderwa cyanyuma cya Kanseri Gufasha abarwayi nimiryango yabo bihangana ningaruka zumubiri nirangamutima byindwara. Amatsinda ashyigikira, ubujyanama, hamwe nubuvuzi bwa palliative burashobora gutanga ubufasha bwingirakamaro. Kugumana ubuzima bwiza, harimo indyo yuzuye hamwe nimyitozo ngororamubiri, irashobora kandi kuzamura imibereho. Kuganira kubibazo nibibazo hamwe nitsinda ryanyu ryubuzima ni ngombwa kugirango ucukumbire LCLC neza. Inkunga yumutungo itanga inkunga nubutunzi kubantu basuzumye LCLC nimiryango yabo. Ibi bikoresho harimo ibikoresho byuburezi, amatsinda ashyigikira, gahunda zifasha mu mafaranga, hamwe nubuvugizi. Guhuza naya mutungo birashobora gutanga inkunga nubuyobozi mu rugendo mu rugendo rwa kanseri.INGINGO: Umuryango w'Abanyamerika wa Oncologiya (ASCO): Kanseri y'ibihaha - Akagari Ntoya: Imibare.